Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Humanin

HN, S14G-Humanin

Quick Stats
Studies 491
Trials 100
Score 2
2003 pubmed 77 citations

Humanin rescues human cerebrovascular smooth muscle cells from Abeta-induced toxicity.

Jung. Sonia S SS; Van Nostrand. William E WE

Key Findings

  • Humanin at 10 µM prevented amyloid‑beta‑induced death of cerebrovascular smooth muscle cells
  • Humanin reduced degradation of the cell’s structural protein alpha‑actin
  • Humanin did not change amyloid‑beta deposition, fibril formation, or levels of amyloid precursor protein

Practical Outcomes

  • Humanin shows promise as a protective agent for brain blood‑vessel cells, but the experiments were done in a dish at high concentrations and didn’t affect amyloid buildup. More animal and human studies are needed before anyone can safely use it, and there’s no clear dosing guidance for self‑experimentation yet.

Summary

The study shows that the small protein humanin can protect human brain blood‑vessel cells from dying when they’re exposed to toxic amyloid‑beta, but it doesn’t stop the amyloid from sticking to the cells or building up. The protection was seen at a relatively high lab dose (10 µM).

Abstract

Cerebral amyloid beta-protein (Abeta) angiopathy (CAA) is a key pathological feature of Alzheimer's disease (AD) and related disorders. We have used human cerebrovascular smooth muscle (HCSM) cells as an in vitro model system to investigate the pathogenic mechanisms of the pathology of CAA. It was previously demonstrated that certain pathogenic forms of Abeta induce several pathologic responses in these cells, including fibril assembly at the cell surface, increased levels of Abeta precursor, degradation of HCSM cell alpha-actin and cell death. The recently discovered novel rescue factor humanin (HN) was shown to protect neuronal cells in culture from various AD-relevant insults including treatment with Abeta. In this report we investigated whether the HN peptide could rescue HCSM cells from Abeta-induced toxicity. We found that treatment of HCSM cells with 10 microm HN prevented pathogenic Abeta-induced HCSM cell death using a fluorescent cell viability assay, and degradation of HCSM alpha-actin was diminished shown by quantitative immunoblotting. However, Abeta deposition and fibril formation at the cell surface and increased levels of cell-associated AbetaPP were not affected by treatment with HN as demonstrated by a thioflavin T fluorescence assay and immunochemical methods, respectively. These results suggest that the protective effects of HN occur downstream of these cell surface molecular events. This is the first demonstration of a rescue factor for HCSM cells from Abeta-mediated cell death as well as being the first report to show that neuronal cells and HCSM cells may share a common downstream mechanism in the Abeta-induced cell death pathway.

Study Information

Provider

pubmed

Year

2003

Date

2003-01-01T00:00:00.000Z

DOI

10.1046/j.1471-4159.2003.01524.x

Citations

77

References

28